Edgewise Therapeutics, Inc. EWTX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -38.1%-3.9pp | -34.2%-4.2pp | -30%-2.6pp | -27.4%+2.9pp | -30.3%+4.1pp | |
| Return on assets | -36.2%-3.9pp | -32.3%-3.6pp | -28.7%-2.4pp | -26.3%+2.7pp | -29%+3.4pp | |
| Return on invested capital | -47.1%-3.9pp | -43.1%-5.6pp | -37.5%-3.3pp | -34.2%+3.9pp | -38%+10.1pp | |
| Liquidity | ||||||
| Current ratio | 22.6×+2.8× | 19.9×-6.7× | 26.5×-2.4× | 28.9×+7.9× | 21×+1.1× | |
| Quick ratio | 22.6×+2.8× | 19.9×-6.7× | 26.5×-2.4× | 28.9×+7.9× | 21×+1.1× | |
| Cash ratio | 1.5×-0.8× | 2.2×+0.1× | 2.1×0.0× | 2.1×-0.3× | 2.4×+0.6× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $4.60-9.3% | $5.07-4.2% | $5.30-5.7% | $5.61+24.3% | $4.52-9.1% | |
| Valuation | ||||||
| Market capitalization | $3.38B+28.6% | $2.63B+53.7% | $1.71B+10.1% | $1.55B-25.9% | $2.09B-17.2% | |
| Enterprise value | $3.35B+30.3% | $2.57B+54.2% | $1.67B+10.2% | $1.51B-26.2% | $2.05B-17.7% | |
| Price / book | 6.9×+1.8× | 5×+2.0× | 3.1×+0.4× | 2.6×-2.2× | 4.9×-0.6× | |
| Free cash flow yield | -4.4%+1.1pp | -5.5%+2.3pp | -7.8%+0.3pp | -8.1%-2.4pp | -5.7%-1.3pp | |
| Earnings yield | -5.2%+1.2pp | -6.4%+2.8pp | -9.2%+0.5pp | -9.7%-2.7pp | -7%-1.7pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Edgewise Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Edgewise Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.